Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Nutriband Inc. develops prescription transdermal pharmaceutical products, with recurring updates centered on its AVERSA abuse-deterrent transdermal technology and a lead abuse-deterrent fentanyl transdermal system. The technology incorporates aversive agents into patches to address abuse, diversion, misuse and accidental exposure involving drugs with abuse potential, including opioids and stimulant drugs.
Company news also covers product distribution activity for kinesiology tapes and mosquito repellent patches, regulatory and intellectual-property steps tied to transdermal products, shareholder meeting matters, and corporate updates involving operating subsidiaries and Nasdaq-listed common stock and warrants.
Nutriband (NASDAQ:NTRB) and its Active Intelligence subsidiary will participate in the June 2026 ECRM conference, meeting buyers from Walmart, Walgreens, Amazon, Cardinal Health and other major retailers.
Active Intelligence will showcase its expanding AI Tape line and launch new AI Performance Tape, AI Energy Patches, and AI Sleep products.
Nutriband (NASDAQ:NTRB) announced on April 22, 2026 that CEO and co-founder Gareth Sheridan appeared on the Jack Neel Podcast to discuss the US fentanyl/opioid crisis, Nutriband’s AVERSA technology and the company’s opportunity to improve safety for easily abused medications.
The episode is available on YouTube, Spotify, iTunes, Amazon Music and jackneel.com for shareholders and interested parties.
Nutriband (NASDAQ:NTRB) selected a worldwide commercial brand name candidate for its lead product, an abuse‑deterrent fentanyl transdermal system, and will submit the proposed name and labeling to the FDA and other international regulators.
The company also filed for U.S. and international trademark protection, engaged Brand Institute for naming, and cites potential peak U.S. sales of $80M–$200M. The product uses Nutriband’s AVERSA abuse‑deterrent transdermal technology and is covered by patents in 46 countries.
Nutriband (NASDAQ: NTRB) announced that the Costa Rica Ministry of Health approved its line of kinesiology tapes for import and sale on March 18, 2026. The approval covers the Company’s Kinesiology Line, AVERSA products and mosquito repellent patches.
The Company said its exclusive Costa Rica distributor, Innomedica CCB S.A., oversaw and financed the regulatory approval process. Nutriband and Innomedica plan to begin ramping up marketing and distribution in Costa Rica following this approval.
Nutriband (NASDAQ: NTRB) signed an exclusive distribution agreement with Costa Rica-based Innomedica for AVERSA fentanyl (upon approval) and all sports tape products manufactured at its Pocono Pharmaceutical / Active Intell subsidiary.
Innomedica will manage and finance regulatory approvals as products ramp up for launch in Costa Rica.
Nutriband (NASDAQ: NTRB / NTRBW) summarized key points from its Jan 24, 2026 annual shareholder meeting in Orlando. Highlights include board additions, AVERSA™ FENTANYL development progress, patent milestones, manufacturing scale-up, a Type C meeting with the US FDA, planned IND and HAL clinical trial work, ongoing Pocono Pharma sale activity, a FINRA complaint, and 2026 warrant expirations.
Notable specifics: exclusive development partnership with Kindeva, new patents in the US and Macao, collection of $30,000 in closing-extension penalties, and 91,0904 warrants expiring Oct 1, 2026 with $6.43 strike.
Nutriband (NASDAQ:NTRB / NTRBW) CEO Gareth Sheridan published a shareholder letter summarizing 2025 milestones and 2026 outlook. Key 2025 developments include a $5M sale for 90% of the Pocono subsidiary to EarthVision Bio, a 25% preferred stock dividend issued July 25, 2025 (convertible on FDA approval of AVERSA Fentanyl), and USPTO patent issuance No. 12,318,492 on June 3, 2025 covering abuse‑deterrent transdermal systems.
Other items: commercial manufacturing scale‑up completed in June 2025, a Type C meeting with FDA on CMC and pathway to a 505(b)(2) NDA, addition to four Russell indexes, and warrants from the 2021 IPO expiring Oct 1, 2026.
Nutriband (NASDAQ: NTRB / NTRBW) signed an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical to EarthVision Bio for $5.0 million. Shareholders will retain a 10% stake in EarthVision Bio after the transaction. The expected closing date is Dec 31, 2025. Nutriband said it will use sale proceeds to fund continued development of AVERSA Fentanyl, described as a potential abuse‑deterrent transdermal fentanyl patch. The company disclosed projected potential US annual sales for AVERSA Fentanyl of $80M–$200M.
EarthVision Bio is described as commercializing sustainable products developed by Dr. Gordon Moore and Dr. Hans Franke; Nutriband will no longer hold majority control of Pocono Pharmaceutical after closing.
Nutriband (NASDAQ: NTRB / NTRBW) announced a non-binding Letter of Intent dated Dec 18, 2025 to explore advanced technology collaboration with Qvanta Group of Companies.
The LOI contemplates joint evaluation of quantum‑ready AI simulation, secure high‑performance computing, and cybersecurity/data‑integrity frameworks to support Nutriband’s abuse‑deterrent pharmaceutical research and product development. The parties will emphasize regulatory compliance and data protection. The LOI is non‑binding and expressly states there is no assurance a definitive agreement or transaction will occur.
Nutriband (NASDAQ:NTRB) announced development of AVERSA™ FENTANYL, an abuse‑deterrent transdermal fentanyl system combining Nutriband’s AVERSA™ technology with Kindeva’s FDA‑approved fentanyl patch.
The company positioned this program in response to the U.S. Executive Order designating illicit fentanyl and core precursors as weapons of mass destruction (Dec 15, 2025), while stressing that FDA‑approved prescription fentanyl remains medically necessary. Nutriband cites ongoing abuse/accidental exposure risks and projects peak annual U.S. sales of $80M–$200M for AVERSA™ FENTANYL. The AVERSA™ IP portfolio includes patents issued in 46 countries.